Abstract
Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality.
Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.Keywords: Cerebral ischemia, conversion, hemorrhagic transformation, prevention, stroke, treatment.
Graphical Abstract
Current Drug Targets
Title:Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation
Volume: 18 Issue: 12
Author(s): Wing Mann Ho, Cesar Reis, Onat Akyol, Gokce Yilmaz Akyol, Richard Applegate II, Gary Stier, Robert Martin and John H. Zhang*
Affiliation:
- Department of Neurosurgery, Loma Linda University Medical Center, 11234 Anderson Street, Room 2562B, Loma Linda, CA 92354,United States
Keywords: Cerebral ischemia, conversion, hemorrhagic transformation, prevention, stroke, treatment.
Abstract: Background: Hemorrhagic transformation (HT) is a common and natural complication after acute ischemic stroke. The only FDA-approved treatment so far for acute ischemic stroke is rapid reperfusion with recombinant tissue plasminogen activator (rtPA). Although it has been shown to exaggerate the risk and severity of HT and to be associated with increased morbidity and mortality.
Objective: The aim of this review is to discuss the multifactorial pathophysiology of hemorrhagic transformation, promising interventional targets, and pharmacological treatment options. Results and Conclusion: Understanding HT is essential to restore cerebral blood flow to ischemic brain by reperfusion therapy without causing this complication and additional brain injury. Therefore methods for the prevention and treatment of HT are needed. Although experimental studies showed promising results, clinical translation remains unsatisfactory to date.Export Options
About this article
Cite this article as:
Ho Mann Wing, Reis Cesar, Akyol Onat, Akyol Yilmaz Gokce, Applegate II Richard, Stier Gary, Martin Robert and Zhang H. John*, Pharmacological Management Options to Prevent and Reduce Ischemic Hemorrhagic Transformation, Current Drug Targets 2017; 18 (12) . https://dx.doi.org/10.2174/1389450117666160818115850
DOI https://dx.doi.org/10.2174/1389450117666160818115850 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
DHA: An Excellent Source of Bioactive Heterocycles
Letters in Organic Chemistry Metalloproteinase-Mediated Shedding of Heparin-Binding Egf-Like Growth Factor and Its Pathophysiological Roles
Protein & Peptide Letters Mechanisms of Antihistamines and Mast Cell Stabilizers in Ocular Allergic Inflammation
Medicinal Chemistry Reviews - Online (Discontinued) Microglial Activation and its Implications in the Brain Diseases
Current Medicinal Chemistry Crosstalk Between Covid-19 and Associated Neurological Disorders: A Review
Current Neuropharmacology Phytotherapy for the Prevention of Atherosclerosis-Associated Early Cerebral Ischemia
Current Drug Metabolism Disrupted Functional Connectivity Related to Differential Degeneration of the Cingulum Bundle in Mild Cognitive Impairment Patients
Current Alzheimer Research Endotoxin, Toll-like Receptor-4, and Atherosclerotic Heart Disease
Current Cardiology Reviews Current Clinical Applications of Botulinum Toxin
Current Pharmaceutical Design Pharmacology of L-type Calcium Channels: Novel Drugs for Old Targets?
Current Molecular Pharmacology Are the Extracelluar Pathways a Conduit for the Delivery of Therapeutics to the Brain?
Current Pharmaceutical Design Pharmaconutrition with Omega-3 Fatty Acids: Status Quo and Further Perspectives
Mini-Reviews in Medicinal Chemistry Artery of Percheron Infarction: A Characteristic Pattern of Ischemia and Variable Clinical Presentation: A Literature Review
Current Medical Imaging Neuroinflammation: Microglial Activation During Sepsis
Current Neurovascular Research The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Current Medicinal Chemistry Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology Alert Cell Strategy: Mechanisms of Inflammatory Response and Organ Protection
Current Pharmaceutical Design Autophagy and Cell Death in Caenorhabditis elegans
Current Pharmaceutical Design Current Drugs and Potential Future Neuroprotective Compounds for Parkinson’s Disease
Current Neuropharmacology A Needle-Free Approach for Topical Immunization: Antigen Delivery via Vesicular Carrier System(s)
Current Medicinal Chemistry